RxDoctor Payments Data

Amanda Christopher Thomas, PA

Physician Assistant · Charlotte, NCNPI 1558734137

Payments from drug & device makers

$14,464in general payments, 2019–2025

Across 878 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$1K
  • Lilly USA, LLC$984
  • GSK$978
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$869
  • AstraZeneca$828
  • plus $7K from 47 others

What the payments were for

  • Speaking & faculty fees$310%
  • Food & beverage$14,434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,464 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$15,581
Medicare patients
43
Services billed
391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide35$34,941
FarxigaDapagliflozin Propanediol25$27,244
OzempicSemaglutide27$25,768
VascepaIcosapent Ethyl18$19,768
JardianceEmpagliflozin18$12,806
GemtesaVibegron12$9,281
Rosuvastatin Calcium94$1,386
SynthroidLevothyroxine Sodium12$1,135
Omeprazole45$1,071
Atorvastatin Calcium136$1,048
Temazepam16$1,040
Gabapentin58$799
Diclofenac Sodium74$717
Memantine Hcl13$680
Levothyroxine Sodium55$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$984$34,94135 claims
AstraZenecaFarxiga$828$27,24425 claims
Novo NordiskOzempic$1,300$25,76827 claims
Boehringer IngelheimJardiance$583$12,80618 claims
Sumitomo Pharma America, Inc.Gemtesa$357$9,28112 claims
AbbVieSynthroid$2,806$1,13512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →